196 related articles for article (PubMed ID: 26567123)
1. Incidence, characteristics and impact of hypoglycaemia in patients receiving intensified treatment for inadequately controlled type 2 diabetes mellitus.
Tschöpe D; Bramlage P; Schneider S; Gitt AK
Diab Vasc Dis Res; 2016 Jan; 13(1):2-12. PubMed ID: 26567123
[TBL] [Abstract][Full Text] [Related]
2. [The efficacy and safety of linagliptin in elderly patients with type 2 diabetes: a pooled analysis of eight placebo-controlled clinical trials].
Guo XH; Feng ZK; Xu LH
Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):588-594. PubMed ID: 28789492
[No Abstract] [Full Text] [Related]
3. Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease.
McGill JB; Yki-Järvinen H; Crowe S; Woerle HJ; von Eynatten M
Diab Vasc Dis Res; 2015 Jul; 12(4):249-57. PubMed ID: 25941160
[TBL] [Abstract][Full Text] [Related]
4. Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysis.
Rathmann W; Kostev K; Gruenberger JB; Dworak M; Bader G; Giani G
Diabetes Obes Metab; 2013 Jan; 15(1):55-61. PubMed ID: 22862879
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study).
Ahn CH; Han KA; Yu JM; Nam JY; Ahn KJ; Oh TK; Lee HW; Lee DH; Kim J; Chung CH; Park TS; Kim BJ; Park SW; Park HK; Lee KJ; Kim SW; Park JH; Ko KP; Kim CH; Lee H; Jang HC; Park KS
Diabetes Obes Metab; 2017 May; 19(5):635-643. PubMed ID: 28026912
[TBL] [Abstract][Full Text] [Related]
6. Comparative cardiovascular risks of dipeptidyl peptidase 4 inhibitors with other second- and third-line antidiabetic drugs in patients with type 2 diabetes.
Ou HT; Chang KC; Li CY; Wu JS
Br J Clin Pharmacol; 2017 Jul; 83(7):1556-1570. PubMed ID: 28109184
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study.
Seufert J; Pegelow K; Bramlage P
Vasc Health Risk Manag; 2013; 9():711-7. PubMed ID: 24259985
[TBL] [Abstract][Full Text] [Related]
8. Association of dipeptidyl peptidase-4 inhibitor initiation at glycated haemoglobin <7.5% with reduced major clinical events mediated by low glycated haemoglobin variability.
Cheung JTK; Yang A; Wu H; Lau ESH; Lui J; Kong APS; Ma RCW; Luk AOY; Chow E; Chan JCN
Diabetes Obes Metab; 2024 Aug; 26(8):3339-3351. PubMed ID: 38802991
[TBL] [Abstract][Full Text] [Related]
9. Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials.
Monami M; Cremasco F; Lamanna C; Marchionni N; Mannucci E
Diabetes Metab Res Rev; 2011 May; 27(4):362-72. PubMed ID: 21309062
[TBL] [Abstract][Full Text] [Related]
10. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK
PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea.
Kang YM; Jung CH; Lee SH; Kim SW; Song KH; Kim SG; Kim JH; Cho YM; Park TS; Ku BJ; Koh G; Kim DM; Lee BW; Park JY
Diabetes Metab J; 2019 Aug; 43(4):432-446. PubMed ID: 31237133
[TBL] [Abstract][Full Text] [Related]
12. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus.
Meneghini LF; Traylor L; Schwartz SL
Endocr Pract; 2010; 16(4):588-99. PubMed ID: 20350924
[TBL] [Abstract][Full Text] [Related]
13. Changes in incidence of severe hypoglycaemia in people with type 2 diabetes from 2006 to 2016: analysis based on health insurance data in Germany considering the anti-hyperglycaemic medication.
Müller N; Lehmann T; Klöss A; Günster C; Kloos C; Müller UA
Diabet Med; 2020 Aug; 37(8):1326-1332. PubMed ID: 32145093
[TBL] [Abstract][Full Text] [Related]
14. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
Karagiannis T; Paschos P; Paletas K; Matthews DR; Tsapas A
BMJ; 2012 Mar; 344():e1369. PubMed ID: 22411919
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of adding pioglitazone or sitagliptin to patients with type 2 diabetes insufficiently controlled with metformin and a sulfonylurea.
Liu SC; Chien KL; Wang CH; Chen WC; Leung CH
Endocr Pract; 2013; 19(6):980-8. PubMed ID: 23807528
[TBL] [Abstract][Full Text] [Related]
16. Risk of hypoglycemia following intensification of metformin treatment with insulin versus sulfonylurea.
Roumie CL; Min JY; Greevy RA; Grijalva CG; Hung AM; Liu X; Elasy T; Griffin MR
CMAJ; 2016 Apr; 188(6):E104-E112. PubMed ID: 26811361
[TBL] [Abstract][Full Text] [Related]
17. Treatment intensification for patients with type 2 diabetes and poor glycaemic control.
Fu AZ; Sheehan JJ
Diabetes Obes Metab; 2016 Sep; 18(9):892-8. PubMed ID: 27160505
[TBL] [Abstract][Full Text] [Related]
18. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
Ou HT; Chang KC; Li CY; Wu JS
Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
[TBL] [Abstract][Full Text] [Related]
19. Incidence of and risk factors for severe hypoglycaemia in treated type 2 diabetes mellitus patients in the UK--a nested case-control analysis.
Bruderer SG; Bodmer M; Jick SS; Bader G; Schlienger RG; Meier CR
Diabetes Obes Metab; 2014 Sep; 16(9):801-11. PubMed ID: 24612200
[TBL] [Abstract][Full Text] [Related]
20. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Lo C; Toyama T; Oshima M; Jun M; Chin KL; Hawley CM; Zoungas S
Cochrane Database Syst Rev; 2020 Jul; 8(8):CD009966. PubMed ID: 32803882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
